Sionna Therapeutics (SION) Common Equity (2024 - 2026)

Sionna Therapeutics (SION) has 3 years of Common Equity data on file, last reported at $288.2 million in Q1 2026.

• For the quarter ending Q1 2026, Common Equity fell 18.07% year-over-year to $288.2 million; the trailing twelve-month figure through Mar 2026 stood at $288.2 million (down 18.07% YoY), and the FY2025 full-year result was $306.8 million, up 287.42% from the prior year.
• Common Equity eased to $288.2 million in Q1 2026, from $306.8 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $351.8 million in Q1 2025 to a low of -$163.7 million in Q4 2024.
• A 3-year average of $114.8 million and a median of $288.2 million in 2026 frame the typical range for Common Equity.
• Across the five-year window, Common Equity surged 379.0% in 2025 and declined 18.07% in 2026, its largest moves.
• Tracing SION's Common Equity over 3 years: stood at -$163.7 million in 2024, then surged by 287.42% to $306.8 million in 2025, then fell by 6.07% to $288.2 million in 2026.
• Business Quant data shows SION's Common Equity at $288.2 million in Q1 2026, $306.8 million in Q4 2025, and $321.7 million in Q3 2025.